Skip to main content
. Author manuscript; available in PMC: 2014 Apr 3.
Published in final edited form as: Circ Res. 2011 Nov 17;110(2):241–252. doi: 10.1161/CIRCRESAHA.111.250126

Figure 8.

Figure 8

Less Risk of Teratoma Formation from iVPCs than from iPSCs. A. Morphology of iPSC, iVPC and clone #9 (named as iVPC/iPSC because ES-cell-like fully reprogrammed cells appeared in the iVPCs). B. When seeded on low attachment dishes with differentiation medium, iPSC grew in suspension, aggregated and formed embryo bodies. In contrast, iVPCs attached to the plates and spread, and did not from embryo bodies. C. Kidneys and testis harvested after injection with iPSC, iVPCs and iVPCs/iPSCs. iVPCs did not form teratomas while iPSCs and iVPCs formed teratomas. D shows the probabilities of teratoma formation from iVPCs, iPSCs and iVPC/iPSC. 1 refers the teratoma formed and 0 refers no teratoma formed. The “N” refers to injection times. So for iPSCs, the probability of teratoma formation was 100% (4 out of 4). For iVPC, the probability of teratoma formation is 0% (0 out of 15). For iVPC/iPSC, the probability of teratoma formation is 100% (3 out of 3). Even if including iVPC/iPSC (clone#9), the probability of teratoma formation of iVPCs is 0.46% (3 out of 18 injections in the context of one clone out of 36 clones became iVPC/iPSC). Scale bar equals 100μm.